Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002,...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of SYRE is 53 and suggests 45% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell